New trial recruiting!!! Pembro plus MGA271 for folks (melanoma, urothelial cancer and more) who progressed on systemic therapy including immuno!!!

Y'all know I am apt to get excited about small things...but....this seems to hold real promise for folks who have progressed on a variety of treatments.  This study combines MGA271 with pembro for a variety of folks with solid tumors.  So what is this MGA271?  At the moment it is called Enoblituzumab, a B7-H3 monoclonal antibody.  Here's a link to a presentation that explains, followed by selected slides:

Interim results of an ongoing Phase 1, Dose escalation study of MGA271 (Enoblituzumab) an Fc-optimized humanized Anti-B7-H3 monoclonal antibody, in patients with advanced solid cancer

 

What is super cool about all of this...is....  See the second line on the slide above?  These folks are POST ipi, anti-PD1 or some various combo of the two!!!

Here is a link to a report of the new trial for Enoblituzumab combined with Pembro:  A Phase I, open-label, dose escalation study of MGA271 in combination with pembrolizumab in patients with B7-H3-expressing cancer

Here's a link to the study at ClinicalTrials.gov:  Safety Study of MGA271 in Combination With Pembrolizumab in Refractory Cancer

The trial seems to be actively recruiting in Baltimore, New York, Philadelphia, and San Antonio.  Now this is a Phase 1 study...making the ratties - ratties for realz!!! But....everybody gets the drug.  Just thinking this may be a real option for folks for whom neither ipi nor the anti-PD1 products worked.  (We'll keep looking at how it does, Joshie!!!!)

Good thing ratties have long tails!!!  love, c